Hoffmann, Christian and Hentrich, Marcus and Tiemann, Markus and Rosenwald, Andreas and Weber, Florian and Willenbacher, Wolfgang and Huebel, Kai (2022) Recent Advances in Castleman Disease. ONCOLOGY RESEARCH AND TREATMENT, 45 (11). pp. 693-704. ISSN 2296-5270, 2296-5262
Full text not available from this repository. (Request a copy)Abstract
Background: Castleman disease (CD) encompasses a spectrum of rare disorders with characteristic histopathological features. Unicentric Castleman disease (UCD) is a benign, local hyperplasia of lymphoid tissue that is usually curable. Multicentric Castleman disease (MCD) manifests as a potentially life-threatening systemic disease with complex symptomatology which is mostly due to an overproduction of interleukin-6 (IL-6) or dysregulation of IL-6-related signaling pathways. From a therapeutic perspective, it is important to distinguish idiopathic MCD (iMCD) from those cases that are associated with the human herpes virus 8 (HHV-8+MCD). Summary: During recent years, it has become increasingly clear that even HHV-8-negative MCD is not a homogeneous entity and that there are clinically distinct variants. International consensus guidelines for diagnosis and treatment have been developed for iMCD and UCD. Key messages: We herein summarize recent advances in diagnosis, treatment and novel insights into the pathogenesis of this disease.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | LYMPH-NODE HYPERPLASIA; TREATMENT GUIDELINES; DIAGNOSTIC-CRITERIA; CLINICAL-FEATURES; VIRAL LOAD; RITUXIMAB; CYTOKINE; INTERLEUKIN-6; SPECTRUM; SUBTYPE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Pathologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 28 Feb 2024 13:38 |
| Last Modified: | 28 Feb 2024 13:38 |
| URI: | https://pred.uni-regensburg.de/id/eprint/58180 |
Actions (login required)
 |
View Item |
